| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/30/2008 | CN101167796A Monascus and red sage root composition for preventing and treating cardiovascular and cerebrovascular diseases |
| 04/30/2008 | CN101167795A Capsule for preventing cardiovascular and cerebrovascular diseases |
| 04/30/2008 | CN101167793A Walnut oil fat emulsion and manufacturing method thereof |
| 04/30/2008 | CN101167784A Medicinal composition for cardiovascular and cerebrovascular diseases |
| 04/30/2008 | CN101167775A Method for extracting chrysanthemum total flavone |
| 04/30/2008 | CN101167773A Medicine composition for treating cardiac and cerebral vascular diseases |
| 04/30/2008 | CN101167767A Hypericum attenuatum extraction and its application |
| 04/30/2008 | CN101167766A Didymocarpus eburneus extraction, preparation method and application thereof |
| 04/30/2008 | CN101167763A Monascus and total ginkgolide composition for preventing and treating cardiovascular and cerebrovascular diseases |
| 04/30/2008 | CN101167733A Venous injection powder injection for preventing and treating ischemic cerebral apoplexy and preparation method thereof |
| 04/30/2008 | CN101167728A Doxazosin-mesylate controlled-releasing tablet and preparation method thereof |
| 04/30/2008 | CN101167725A Nimodipine long circulating vesicle and its freezing-dried preparation |
| 04/30/2008 | CN101167723A Valsartan dispersible tablet and preparation method thereof |
| 04/30/2008 | CN101167717A Novel isosorbide mononitrate injection |
| 04/30/2008 | CN101167708A New use of 6,7-dehydroroyleanone in pharmaceutical |
| 04/30/2008 | CN101167700A Nifedipine controlled-releasing tablet and preparation method thereof |
| 04/30/2008 | CN101167695A Composition with improved light stability |
| 04/30/2008 | CN101167575A Tea polysaccharide lozenge |
| 04/30/2008 | CN100385005C Methods for the production of multimeric proteins, and related compositions |
| 04/30/2008 | CN100384991C High purity kallidinogenase prepartion method and its pharmaceutical formulation |
| 04/30/2008 | CN100384981C Red rice mould mutant strain and its use in preparing fermented product with blood pressure reducing activity |
| 04/30/2008 | CN100384863C Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof |
| 04/30/2008 | CN100384852C Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase |
| 04/30/2008 | CN100384844C Xanthine phosphodiesterase V inhibitor polymorphs |
| 04/30/2008 | CN100384841C Polymorphic forms of 1-4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 04/30/2008 | CN100384836C Novel cyclic amide derivatives |
| 04/30/2008 | CN100384830C Derivative of cyclo membranousol kind and application thereof |
| 04/30/2008 | CN100384825C Benzheterocyclic derivatives |
| 04/30/2008 | CN100384821C Cetp activity inhibitors |
| 04/30/2008 | CN100384820C Phosphate prodrugs of fluorooxindoles |
| 04/30/2008 | CN100384485C Microbiological cellulose injury dressing for treating chronic injury |
| 04/30/2008 | CN100384482C Method of examining effect of angiogenesis inhibitors mediated by the inhibition of integrin expression |
| 04/30/2008 | CN100384480C Delivery system for nucleic acids |
| 04/30/2008 | CN100384477C Complex of modafinil and cyclodextrin |
| 04/30/2008 | CN100384466C Chinese proprietary medicine for regulating blood pressure and application thereof |
| 04/30/2008 | CN100384442C Chinese herbal medicine preparation and its preparing process and application |
| 04/30/2008 | CN100384439C Medicinal composition for treating and/or preventing heart brnin blood vessel disease and its preparation method |
| 04/30/2008 | CN100384437C Botanical medicine for preventing and treating arteriosclerosis and regulating blood fat and its processing method |
| 04/30/2008 | CN100384430C Combination therepy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 04/30/2008 | CN100384429C Capsule for treating cardiac and cerebral vascular diseases and its preparing method and application |
| 04/30/2008 | CN100384428C Oral disintegrating tablet of notoginseng triterpenes and preparation method thereof |
| 04/30/2008 | CN100384416C Medicinal composition for treating cerebrovascular disease |
| 04/30/2008 | CN100384414C Medicine containing ketone effective component |
| 04/29/2008 | USRE40278 Heterocyclic amines having central nervous system activity |
| 04/29/2008 | US7365205 Diamine derivatives |
| 04/29/2008 | US7365172 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor; stimulate hematopoiesis; diabetes, rheumatoid arthritis, lupus, and multiple sclerosis |
| 04/29/2008 | US7365170 Reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents |
| 04/29/2008 | US7365155 Immunoregulator |
| 04/29/2008 | US7365089 Triazolo-quinolin derivatives useful as adenosine receptor ligands |
| 04/29/2008 | US7365085 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol; agonists of the nuclear receptors, LXR alpha and LXR beta used to increase ABCA1, ABCG1, and apolipoprotein E expression and inhibiting cholesterol absorption |
| 04/29/2008 | US7365084 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals |
| 04/29/2008 | US7365083 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 04/29/2008 | US7365077 Obesity, type 2 diabetes, sleep disorders, ischaemic or haemorrhagic strokes, antiemetic; toxicity; side effect reduction; 2-((benzofuran-4-yl)carbonylaminomethyl)-1-((4-(5-(4-fluorophenyl)-2-methyl)thiazolyl)carbonyl)-4-methylpiperazine |
| 04/29/2008 | US7365067 Neurokinin receptors antagonists; asthma, bronchitis and chronic obstructive lung disease; allergic diseases such as rhinitis, urinary incontinence; 1-(2-{(2R)-2-(3,4dichlorophenyl)-4-[3,5-bis(trifluoromethyl)benzoyl]morpholin-2-yl}ethyl)spiro((2S)-2-{[(morpholin-1-yl)acetyl]oxy})indane-1,4'-piperidine |
| 04/29/2008 | US7365064 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them |
| 04/29/2008 | US7365062 4-(2-fluorophenylbenzoyl-4-aminobenzoyl)-3'-(2-(N,N-dimethylaminoethylaminocarbonyl))-4-aza-[6,4]-spiro-[5,6]-benzoundec-2'-ene; hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema or ischemia |
| 04/29/2008 | US7365049 Afamin-containing compositions and methods of use |
| 04/29/2008 | US7364757 Methods of treating vascular disease |
| 04/29/2008 | US7364751 By adding an antioxidant and/or a chelating agent in the same aqueous solution; reduced coenzyme Q10, vitamin C and ethylenediaminetetracetic acid for example |
| 04/29/2008 | US7364719 Vasoregulating compounds and methods of their use |
| 04/29/2008 | CA2567582C Anti-hypertensive dietary supplement derived from salmo or oncorhynchus protein hydrolysates |
| 04/29/2008 | CA2416492C Treatment of glycogen storage disease type ii |
| 04/29/2008 | CA2394037C New derivatives of benzene sulfonamide, their preparation process and pharmaceutical compositions that contain them |
| 04/29/2008 | CA2343204C Arylsulfonanilide ureas |
| 04/29/2008 | CA2336474C C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 04/29/2008 | CA2304712C Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| 04/29/2008 | CA2254833C Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| 04/29/2008 | CA2218887C Piperazino derivatives as neurokinin antagonists |
| 04/24/2008 | WO2008049047A2 Quinoline compounds |
| 04/24/2008 | WO2008048084A1 Pharmaceutical combinations for the treatment of dyslipidemia accompanied by high blood pressure |
| 04/24/2008 | WO2008048083A1 Pharmaceutical compositions for the treatment of thromboembolic diseases |
| 04/24/2008 | WO2008047904A1 Therapeutic agent for occlusive peripheral vascular disease, and use thereof |
| 04/24/2008 | WO2008047863A1 Sustained release preparation for tissue regeneration therapy |
| 04/24/2008 | WO2008047821A1 Fused heterocyclic compound |
| 04/24/2008 | WO2008047544A1 Diaryl ketimine derivative |
| 04/24/2008 | WO2008047486A1 Myocardial injury-controlling agent |
| 04/24/2008 | WO2008046598A1 DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR |
| 04/24/2008 | WO2008020206A3 Fused thiophene derivatives as mek inhibitors |
| 04/24/2008 | WO2008009638A3 New indications for direct thrombin inhibitors in the cardiovascular field |
| 04/24/2008 | WO2007144082A3 Combination antihypertensive wafer |
| 04/24/2008 | WO2006130174A3 Compositions comrising nebivolol |
| 04/24/2008 | US20080097117 chemical intermediates for making antiinflammatory agents treating autoimmune disease; 1-[2-(Fluoren-3-yl)ethyl]-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine drug |
| 04/24/2008 | US20080097109 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 04/24/2008 | US20080096982 evaluating bucindolol treatment for patient with heart failure; whether to administer bucindolol based on if the patient is homozygous for the Arg 389 polymorphism in the .beta.1-adrenergic receptor; bucindolol not indicated wherein the patient is a Del322-325 carrier in alpha2cAR; pharmacogenetics |
| 04/24/2008 | US20080096967 Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals |
| 04/24/2008 | US20080096952 Methods for the treatment of atherosclerosis, using substituted phenethylsulfones |
| 04/24/2008 | US20080096951 Carvedilol Monocitrate Monohydrate |
| 04/24/2008 | US20080096949 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 04/24/2008 | US20080096942 Beta-secretase inhibitors; use in treating Alzheimer's disease; for example, N-{(1S,2R)-1-[3-(cyclohexylmethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}acetamide hydrochloride |
| 04/24/2008 | US20080096936 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 04/24/2008 | US20080096927 Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events |
| 04/24/2008 | US20080096923 Determining the severity of retinopathy, neuropathy, and nephropathy; administering 8, 16, or 32 mg one to three times per day of ruboxistaurin, enzastaurin, PKC 412, candesartan cilexetil, fidarestat, lidorestat, pyridoxamine, pegaptanib, or ranibizumab |
| 04/24/2008 | US20080096922 N-{[cis-1-(3-methoxyphenyl)-4-(piperidin-4-ylamino)-cyclohexyl]methyl}sulfamide diHCL; tert-butyl [({[cis-4-[(biphenyl-4-ylmethyl)amino]-1-(3-methoxyphenyl)cyclohexyl]methyl}amino)sulfonyl]carbamate; for potentiating expression of low density lipoprotein recepotr; arteriosclerosis; hyperlipidemia |
| 04/24/2008 | US20080096908 Nitrate derivatives of atorvastatin with improved pharmacological activity and enhanced tolerability; coronary syndromes, neurodegenerative disorders, and for reducing cholesterol levels; antiinflammatory, antithrombotic and antiplatelet activity; fluvastatin 4-(nitrooxy)butyl ester |
| 04/24/2008 | US20080096900 and coronary, inflammation, thrombosis; anticholesterol agent modifies LCAT polypeptide, Lecithin-cholesterol acyltransferase; wherein the cysteine residue is modified by replacing the thiol hydrogen with 3-pyrazinyl-2-carbonitrile; 3-(5-(methylthio)-1,3,4-thiadiazol-2-ylthio)pyrazine-2-carbonitrile |
| 04/24/2008 | US20080096887 Benzene, Pyridine, and Pyridazine Derivatives |
| 04/24/2008 | US20080096880 Use of imidazo[1,2,4]triazinones which are inhibitors of cGMP-metabolizing phosphodiesterases (PDE I, II and V) to treat cardiovascular disorders, urogenital disorders, prostate hyperplasia, ocular disorders such as glaucoma, optic neuropathy, diabetic gastroparesis, dementia |
| 04/24/2008 | US20080096866 Complex Formulation Of 3-Hydroxy-3-Methyl Glutaryl Coa Reductace Inhibitor And Antihypertensive Agent, And Process For Preparing Same |
| 04/24/2008 | US20080096865 Improved photodynamic treatment against subfoveal choroidal neovascularization; administering midostaurin, vatalanib dihydrochloride or octreotide with a photosensitive porphyrin or purpurin; angiogenesis inhibition |
| 04/24/2008 | US20080096841 Using analogs of Lipid A such as Eritoran to treat or prevent mucositis, allograft/graft rejection, arteriosclerosis, atherosclerosis, hepatitis, asthma, and inflammatory bowel disease |